SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 23, 2003
United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)| | | | | |
| Delaware | | 000-26301 | | 52-1984749 |
| |
| |
|
(State or Other
Jurisdiction of
Incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification Number) |
| | | | | |
1110 Spring Street
Silver Spring, MD | | | 20910 | |
| | |
| |
| (Address of Principal Executive Offices) | | | (Zip Code) |
Registrant’s telephone number, including area code:
(301) 608-9292
Item 5. Other Events.
On January 23, 2003, United Therapeutics Corporation (the “Company”) issued a press release announcing that its wholly owned subsidiary, Unither Pharmaceuticals, had commenced patient enrollment in two identical pivotal clinical trials of OvaRex® MAb (oregovomab), its investigational immunotherapeutic monoclonal antibody being developed for the treatment of stage III/IV advanced ovarian cancer following successful completion of front-line therapy.
Item 7. Exhibits
(c) Exhibits
| | | |
| Exhibit No. | | Description of Exhibit |
| |
|
| 99.1 | | Press release dated January 23, 2003 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | | | UNITED THERAPEUTICS CORPORATION |
| |
| Dated: January 24, 2003 | | By: | | /s/ Paul Mahon
Name: Paul A. Mahon
Title: SVP and General Counsel |
EXHIBIT INDEX
| | | |
| Exhibit No. | | Description of Exhibit |
| |
|
| 99.1 | | Press release dated January 23, 2003 |
